Table 1.
Patient characteristics
| Characteristic | Afatinib+Simvastatin | Afatinib | p-value |
|---|---|---|---|
| Age, median (range, yr) | 59 (44-80) | 67 (44-78) | 0.008 |
| Sex | |||
| Male | 32 (88.9) | 27 (84.4) | 0.725 |
| Female | 4 (11.1) | 5 (15.6) | |
| Smoking | |||
| Never | 4 (11.1) | 1 (3.1) | 0.460 |
| Ever | 31 (86.1) | 30 (93.8) | |
| Unknown | 1 (2.8) | 1 (3.1) | |
| Pathology | |||
| Squamous cell carcinoma | 33 (91.7) | 31 (96.9) | 0.616 |
| Other | 3 (8.3) | 1 (3.1) | |
| ECOG PS | |||
| 0-1 | 27 (75.0) | 24 (75.0) | 0.854 |
| 2 | 9 (25.0) | 8 (25.0) | |
| No. of prior chemotherapies | |||
| 1 | 21 (58.3) | 19 (59.4) | 1.000 |
| 2 | 15 (41.7) | 13 (40.6) | |
| EGFR mutation | |||
| Wild type | 32 (88.8) | 28 (87.6) | 1.000 |
| Mutant typea) | 2 (5.6) | 2 (6.2) | |
| Unknown | 2 (5.6) | 2 (6.2) | |
| EGFR FISH | |||
| Negative | 30 (83.4) | 26 (81.3) | 1.000 |
| Positive | 3 (8.3) | 2 (6.2) | |
| Unknown | 3 (8.3) | 4 (12.5) | |
| EGFR IHC | |||
| Negative | 14 (38.9) | 10 (31.3) | 0.698 |
| Positive | 17 (47.2) | 15 (46.9) | |
| Unknown | 5 (13.9) | 7 (21.9) |
ECOG, Eastern Cooperative Oncology Group; PS, performance status; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
a)
Uncommon EGFR mutations were included.